Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incorrect Classification of Pharmaceutical Agent

Incorrect Classification of Pharmaceutical Agent Letters 3. Verstappen M, van Mulligen E, de Jong PHP, van der Helm-Van Mil AHM. continued half-dose treatment or withdrawal of csDMARD. DMARD-free remission as novel treatment target in rheumatoid arthritis: These data will add to the understanding of whether drug- a systematic literature review of achievability and sustainability. RMD Open. free remission can be achievable for patients with RA. 2020;6(1):e001220. doi:10.1136/rmdopen-2020-001220 4. Baker KF, Skelton AJ, Lendrem DW, et al. Predicting drug-free remission in Siri Lillegraven, MD, MPH, PhD rheumatoid arthritis: a prospective interventional cohort study. J Autoimmun. 2019;105:102298. doi:10.1016/j.jaut.2019.06.009 Nina Paulshus Sundlisæter, MD, PhD 5. Baker KF, Sim JPX, Isaacs JD. Biomarkers of tolerance in immune-mediated Espen A. Haavardsholm, MD, PhD inflammatory diseases: a new era in clinical management? Lancet Rheumatol. 2021;3(5):e371-e382. doi:10.1016/S2665-9913(21)00069-2 Author Affiliations: Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway. Corresponding Author: Siri Lillegraven, MD, MPH, PhD, Division of In Reply In response to our study on tapering of csDMARDs in Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, patients with RA in remission, Dr Baker and colleagues dis- N-0319 Oslo, Norway (siri.lillegraven@gmail.com). cuss the potential for successful tapering, and even drug-free Conflict of Interest Disclosures: Dr Haavardsholm reported receiving personal fees http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Incorrect Classification of Pharmaceutical Agent

JAMA , Volume 326 (9) – Sep 7, 2021

Incorrect Classification of Pharmaceutical Agent

Abstract

Letters 3. Verstappen M, van Mulligen E, de Jong PHP, van der Helm-Van Mil AHM. continued half-dose treatment or withdrawal of csDMARD. DMARD-free remission as novel treatment target in rheumatoid arthritis: These data will add to the understanding of whether drug- a systematic literature review of achievability and sustainability. RMD Open. free remission can be achievable for patients with RA. 2020;6(1):e001220. doi:10.1136/rmdopen-2020-001220 4. Baker KF, Skelton AJ, Lendrem DW, et al....
Loading next page...
 
/lp/american-medical-association/incorrect-classification-of-pharmaceutical-agent-0yhjgXHHvH
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.14278
Publisher site
See Article on Publisher Site

Abstract

Letters 3. Verstappen M, van Mulligen E, de Jong PHP, van der Helm-Van Mil AHM. continued half-dose treatment or withdrawal of csDMARD. DMARD-free remission as novel treatment target in rheumatoid arthritis: These data will add to the understanding of whether drug- a systematic literature review of achievability and sustainability. RMD Open. free remission can be achievable for patients with RA. 2020;6(1):e001220. doi:10.1136/rmdopen-2020-001220 4. Baker KF, Skelton AJ, Lendrem DW, et al. Predicting drug-free remission in Siri Lillegraven, MD, MPH, PhD rheumatoid arthritis: a prospective interventional cohort study. J Autoimmun. 2019;105:102298. doi:10.1016/j.jaut.2019.06.009 Nina Paulshus Sundlisæter, MD, PhD 5. Baker KF, Sim JPX, Isaacs JD. Biomarkers of tolerance in immune-mediated Espen A. Haavardsholm, MD, PhD inflammatory diseases: a new era in clinical management? Lancet Rheumatol. 2021;3(5):e371-e382. doi:10.1016/S2665-9913(21)00069-2 Author Affiliations: Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway. Corresponding Author: Siri Lillegraven, MD, MPH, PhD, Division of In Reply In response to our study on tapering of csDMARDs in Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, patients with RA in remission, Dr Baker and colleagues dis- N-0319 Oslo, Norway (siri.lillegraven@gmail.com). cuss the potential for successful tapering, and even drug-free Conflict of Interest Disclosures: Dr Haavardsholm reported receiving personal fees

Journal

JAMAAmerican Medical Association

Published: Sep 7, 2021

References